Farmas USA

https://www.tipranks.com/stocks/sgyp/price-target

Tiene cita este miercoles con la FDA

Biotech is on fire!!!!

Ni todos los gap se cierran , como dice algunos ...este de Zgnx ha sido brutal de la zona de 10 a la zona de 25 en un dia y ha pasado varios meses, ya 

Futures dip as gov't shutdown enters third day

Jan. 22, 2018 6:30 AM ET|By:  Yoel Minkoff, SA News Editor 

As the federal government shutdown enters a third day, U.S. futures are edging down, the dollar is pulling back slightly and Treasury yields are touching 3 1/2-year highs.

The U.S. Senate has scheduled a noon vote for today on a stopgap spending measure, ensuring the federal government will remain closed when the work week begins.

"We have to see if this event is a trigger to change the market trend," said Takafumi Yamawaki, research analyst at JPMorgan Securities.

https://seekingalpha.com/news/3324044-futures-dip-govt-shutdown-enters-third-day?app=1&uprof=37#email_link

---

¿Y qué consecuencias tiene todo ésto en las Bolsas y los mercados? Entre 1976 y 1996 se han producido en el país 17 cierres de la Administración (varios de ellos solo duraron un día). El balance es que en 8 ocasiones las Bolsas subieron y que en las ocasiones que bajaron sólo en 6 la caída superó el 2%.

https://www.ismaeldelacruz.es/consecuencias-del-cierre-parcial-del-gobierno-de-usa/

---

Aunque veo muchas farmas en verde en Pre , 

los premarkets que marca Nasdaq.com van fatal y con mas retraso de lo habitual. no fiarse

CELG -2%

• Array BioPharma (NASDAQ:ARRY) is up 12% premarket on modest volume on the heels of its announcement of updated results from a Phase 3 clinical trial, BEACON CRC, assessing the triplet combination of encorafenib, binimetinib and Eli Lilly's ERBITUX (cetuximab) in patients with BRAF-positive metastatic colorectal cancer (CRC). The data were presented at the ASCO GU Symposium in San Francisco.
• In CRC patients with the BRAF V600E mutation, estimated median progression-free survival (PFS) was 8 months. The confirmed overall response rate (ORR) was 48%, including three complete responders. The ORR was 62% (n=10/16) in patients who received only one prior line of therapy.
• On the safety front, the most common Grade 3 (serious) or Grade 4 (life-threatening) adverse events (AEs) (30 subjects) were fatigue (13.3%), urinary tract infection (10.0%); elevated AST (enzyme biomarker for liver damage) (10.0%) and elevated CK (enzyme biomarker for damage to the heart, muscle or kidney). There were two discontinuations due to treatment-related AEs.
• Enrollment is ongoing. According to ClinicalTrials.gov, the estimated completion date is July 2019.

CELG sub 100 ya ... genial "mi" BO ...

Estoy esperándola
Factible los $95 o le pego el tiro antes?